의약품, 바이오테크놀러지, 진단 관련 사업자의 공동 연구개발 : 제휴 조건, 합의 내용
Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2015-2021
상품코드 : 308759
리서치사 : Current Partnering, a division of Wildwood Ventures Limited
발행일 : 2021년 04월
페이지 정보 : 영문 2700+ Pages
US $ 3,495 ₩ 3,959,000
PDF (Single User License)
US $ 5,245 ₩ 5,941,000
PDF (Multi User License - 2 to 5 Users)
US $ 10,495 ₩ 11,888,000
PDF (Single Site License - 6+ Users)
US $ 17,495 ₩ 19,818,000
PDF (Global License)


한글목차

의약품, 바이오테크놀러지, 진단 관련 사업자의 공동 연구개발(Collaborative R&D) 계약 동향을 조사했으며, 공동 R&D 계약의 구조, 성공요인, 사례 연구, 최근 제휴 계약의 동향, 개발 단계·치료 분야·기술 등 각종 부문별 내역, 주요 대형 계약, 제휴 계약의 재무 조건, 제휴 계약에 적극적인 기업의 개요 등을 정리하여 전해드립니다.

개요

제1장 서론

제2장 공동 R&D 계약의 동향

제3장 공동 R&D 계약의 구조 : 개요

제4장 주요 계약

제5장 주요 25사

제6장 재무 조건

제7장 계약 디렉토리

부록

KSA 19.07.11

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

영문 목차

영문목차

The Global Collaborative R&D Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2015-2021 report provides comprehensive understanding and unprecedented access to the collaborative R&D partnering deals and agreements entered into by the worlds leading healthcare companies.

The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2021 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.

This report provides details of the latest collaborative R&D deals announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date with the latest information, the report provides details of collaborative R&D deals from 2015 to 2021.

There has been a long standing willingness for parties to enter collaborative R&D deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.

Collaborative R&D is a specific type of partnering deal whereby the parties to the deal agree to collaborate on the research and development and subsequently commercialize a compound, product or technology.

There are several forms of a collaborative R&D deal; A traditional collaborative R&D arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subscequent sales of product(s) derived from the intellectual property.

In more recent times, licensing is often the outcome of a successful period of collaborative R&D on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the collaborative R&D agreement governs who has permission to commercialize and what payments are due should commercialization proceed.

The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to comoercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all collaborative R&D deals announced since 2015 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in collaborative R&D as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of collaborative R&D deals. The chapter includes numerous case studies to enable understanding of both pure collaborative R&D deals and multicomponent deals where collaborative R&D forms a part.

Chapter 4 provides a review of the leading collaborative R&D deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a review of the top 25 most active biopharma companies in collaborative R&D. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a comprehensive review of collaborative R&D financials for deals announced since 2015, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.

Chapter 7 provides a comprehensive and detailed review of collaborative R&D deals signed and announced since 2015 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in collaborative R&D dealmaking since 2015.

In addition, a comprehensive appendix is provided organized by company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about collaborative R&D partnering in the research, development and commercialization of technologies and products.

Key benefits

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2021 provides the reader with the following key benefits:

Report scope

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2021 includes:

In Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2021 available deals and contracts are listed by:

The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2021 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:

Benefits

Global Collaborative R&D Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2015-2021 report provides the reader with the following key benefits:

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in collaborative R&D dealmaking

Chapter 3 - Overview of collaborative R&D deal structure

Chapter 4 - Leading collaborative R&D deals

Chapter 5 - Top 25 most active collaborative R&D dealmakers

Chapter 6 - Collaborative R&D deal term financials

Chapter 7 - Collaborative R&D contract directory 2015 - 2021

Appendices

TABLE OF FIGURES

(주)글로벌인포메이션 02-2025-2992 koreainfo@gii.co.jp
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기